報價延遲最少15分鐘:2025/09/18 16:58 EDT
盤後時段
|
||||
|
8.27 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.41
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.50/--
|
|
企業價值
116.79M
|
| 資產負債 |
|
每股賬面淨值
7.36
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
515.82M
|
|
每股收益
7.50
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/18 16:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
